The 5 key players our ALS Treatment report profiles, and other companies free public records show in this market.
In the order our report profiles them, not ranked by sales. Each name opens the company's page with its public records.
| # | Company | Website | Our reports |
|---|---|---|---|
| 1 | Biogen Inc |
biogen.com (opens in a new tab) | 264 reports |
| 2 | Mitsubishi Tanabe Pharma Corporation | — | 66 reports |
| 3 | Amylyx Pharmaceuticals | — | 33 reports |
| 4 | Sanofi |
sanofi.com (opens in a new tab) | 1,386 reports |
| 5 | Cytokinetics | — | 33 reports |
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
| Company | Where public records show them |
|---|---|
| Kenton | |
| Neuralink |
|
Eli Lilly and Company |
|
| Gland | |
Glenmark Pharmaceuticals |
|
| Alkem Laboratories Ltd | |
| Cognixion |
|
| AB Science |
|
| Sandoz | |
| Italfarmaco | |
| RJK Biopharma Ltd |
|
| Shionogi |
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Companies leading the most active studies found with this market's trial search, worldwide (key players included).
Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Company profiles, market shares and strategies come with the full report, with researched size, forecast, growth and segments.
Key players are our report's research. Other companies and trial counts come from free public records, each with its source. Acuitas market figures are not published on this page.